On Jun. 25, 2021, Roche announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemraﾮ (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older).

The EUA was based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients.